Chevon M. Rariy,MD

MD

Medical Director, Endocrinology, CTCA Chicago

Female physician icon
quotation

My goal is to provide compassionate, personalized endocrine-related patient care while utilizing my passion for innovation and technology.

Location
CTCA Chicago
Specialties
Endocrinology
Education
Medical school:

Harvard Medical School, Boston, MA

Residency:

Internal Medicine - Hospital of the University of Pennsylvania, Philadelphia, PA

Fellowship:

Endocrinology, Diabetes and Metabolism - Harvard Medical School’s affiliate Brigham & Women’s Hospital, Boston, MA
Endocrinology, Diabetes and Metabolism - The University of Pittsburgh Medical Center, Pittsburgh, PA

Advanced degrees:

Certificate, Clinical Research - University of Pittsburgh, Pittsburgh, PA

Certifications

Internal Medicine – American Board of Internal Medicine
Endocrinology, Diabetes and Metabolism – American Board of Internal Medicine

As Medical Director of Endocrinology at Cancer Treatment Centers of America® (CTCA), Chicago, Dr. Chevon M. Rariy oversees diagnosing and treating a range of endocrine disorders and dysfunctions. The endocrine system is a collection of hormone-producing glands that regulate the body. The body's endocrine system includes the pancreas, thyroid, parathyroid, pineal, hypothalamus, adrenal and pituitary glands, ovaries and testes. The body relies on endocrine glands to regulate metabolism, reproductive function, overall development, sleep, mood, blood pressure, bone health and body temperature, among a number of other things.

“Working with a multidisciplinary team, I am focused on the endocrine needs of cancer patients and treatment-related side effect management,” says Dr. Rariy. “Some issues I help address include thyroid dysfunction, thyroid cancer, diabetes management, adrenal and pituitary dysfunction and/or tumors, calcium and parathyroid disorders, osteoporosis, hypertension, weight management, and endocrine-related side effects of cancer treatment.” Dr. Rariy also collaborates with CTCA® doctors and clinicians to initiate endocrine oncology-related research and clinical trial opportunities focused on endocrine tumors, precision medicine and genetic testing. She is actively expanding the use of telehealth services to provide timely, quality care to meet the needs of patients at CTCA all sites.

Dr. Rariy joined the CTCA Chicago hospital in September 2019. Board certified in internal medicine, endocrinology, diabetes and metabolism, Dr. Rariy is dedicated to using advanced techniques and tools. She is a member of several professional organizations, including American Diabetes Association, Endocrine Society and American Telemedicine Association.

Dr. Rariy received a Bachelor of Science degree in biology with a minor in chemistry from Duke University. She earned her medical degree from Harvard Medical School in Boston, Massachusetts, then completed a residency in internal medicine at the Hospital of the University of Pennsylvania in Philadelphia, Pennsylvania. She was an endocrinology fellow in endocrinology, diabetes and metabolism at Harvard Medical School’s affiliate, Brigham & Women’s Hospital in Boston, Massachusetts and subsequently a research, clinical fellow and graduate student at the University of Pittsburgh Medical Center in Pittsburgh, Pennsylvania.

Dr. Rariy enjoys traveling and exploring the world. She has had the opportunity to visit many places, most recently Hawaii, Australia and China. She likes learning about different cultures through her travels.

Patient ratings
Star ratings and comments are only available for medical, radiation and gynecologic oncologists. Gynecologic surgical offerings are not included at this time due to a different survey tool required to evaluate these services. CTCA uses a validated Press Ganey® survey, which captures patient experience feedback for the primary oncology services of chemotherapy and radiation therapy at our comprehensive care and research centers. Following industry best practice, star ratings and comments are only published for physicians with a minimum of 30 completed patient surveys.